WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.

Ni, Chen-Xu

WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway. [electronic resource] - Oncotarget Nov 2016 - 79544-79556 p. digital

Publication Type: Journal Article

1949-2553

10.18632/oncotarget.12822 doi


Alkaloids--pharmacology
Animals
Antineoplastic Agents--pharmacology
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Carcinoma, Hepatocellular--drug therapy
Cell Line, Tumor
Cell Proliferation--drug effects
Cell Self Renewal--drug effects
Dose-Response Relationship, Drug
Doxorubicin--pharmacology
Drug Resistance, Neoplasm--drug effects
Epithelial Cell Adhesion Molecule--genetics
Gene Expression Regulation, Neoplastic
Glycogen Synthase Kinase 3 beta--metabolism
Humans
Inhibitory Concentration 50
Liver Neoplasms--drug therapy
Male
Mice, Inbred BALB C
Mice, Nude
Neoplastic Stem Cells--drug effects
Phenotype
Proto-Oncogene Proteins c-akt--metabolism
Quinolizines--pharmacology
Time Factors
Tumor Burden--drug effects
Wnt Signaling Pathway--drug effects
Xenograft Model Antitumor Assays
beta Catenin--metabolism